Dingdang Health Technology Group (9886) H1 2023 earnings summary

Executive summary

• H1 revenue rose 12.9% YoY to RMB2,247.3m, while net loss narrowed 80% to RMB117.4m from RMB585.9m; the comparison benefited from the absence of prior-year preferred-share fair-value losses and tighter operating costs.

• Adjusted net loss was RMB44.1m versus RMB65.7m; adjusted net loss margin improved to 2.0% from 3.3%.

• Operations focused on online-offline integration, supply-chain refinement, user growth and service efficiency; registered users reached 39.2m and online consultations exceeded 4m.

Financial highlights

• Revenue increased to RMB2,247.3m from RMB1,989.8m; cost of revenue rose 18.1% to RMB1,564.4m, faster than revenue growth.

• Gross profit rose to RMB682.9m from RMB664.7m, while gross margin declined to 30.4% from 33.4%, reflecting product mix.

• Loss before income tax was RMB113.6m versus RMB581.5m; 2022 included RMB362.5m of preferred-share fair-value losses and RMB20.0m of listing expenses.

• Basic and diluted loss per share improved to RMB0.08 from RMB0.92.

Outlook and guidance

• Priorities included strengthening online-offline healthcare services, improving technology and warehousing systems, and expanding service density in major cities while steadily exploring additional cities; no numerical guidance was stated.

• Planned development areas included online medical insurance payments, pharmaceutical cold-chain delivery and AI medical services, alongside continued investment in warehousing and distribution capabilities.